|1.||Youn, Yu Seok: 2 articles (02/2014 - 06/2010)|
|2.||Kim, Tae Hyung: 2 articles (02/2014 - 06/2010)|
|3.||Lee, Kang Choon: 2 articles (02/2014 - 06/2010)|
|4.||Byeon, Hyeong Jun: 1 article (02/2014)|
|5.||Lee, Eun Seong: 1 article (02/2014)|
|6.||Choi, Ji Su: 1 article (02/2014)|
|7.||Choi, Seong Ho: 1 article (02/2014)|
|8.||Chae, Su Young: 1 article (06/2010)|
|9.||Lee, Seulki: 1 article (06/2010)|
|10.||Kim, Kwangmeyung: 1 article (06/2010)|
06/01/2010 - "Improved antitumor activity and tumor targeting of NH(2)-terminal-specific PEGylated tumor necrosis factor-related apoptosis-inducing ligand."
06/01/2010 - "These findings show that PEG-HZ-TRAIL administration provides an effective antitumor treatment, which exhibits superior tumor targeting and better inhibits tumor growth, and suggest that PEG-HZ-TRAIL should be considered a potential candidate for antitumor biotherapy."
06/01/2010 - "Although slight activity loss occurred after PEGylation, PEG-HZ-TRAIL showed excellent tumor cell-specific cytotoxic effects via apoptotic pathways with negligible normal cell toxicity. "
06/01/2010 - "Furthermore, in vivo antitumor tests revealed that PEG-HZ-TRAIL treatment enhanced therapeutic potentials compared with HZ-TRAIL in tumor xenograft animal models, and these enhancements were attributed to its better pharmacokinetic properties and tumor-targeting performance. "
|1.||Heterologous Transplantation (Xenotransplantation)